Brief: Inhibikase Therapeutics Provides Safety And Functional Update On Its Phase 1/1B 101 Trial And Its Phase 2 Ikt-148009 201 Trial In Parkinson's Disease

Inhibikase Therapeutics

26/04/2023 13:10

April 26 (Reuters) - Inhibikase Therapeutics Inc
 IKT.O :
    * INHIBIKASE THERAPEUTICS PROVIDES SAFETY AND FUNCTIONAL
UPDATE ON
ITS PHASE 1/1B 101 TRIAL AND ITS PHASE 2 IKT-148009 201 TRIAL IN
PARKINSON'S DISEASE
    * IMPLEMENTED NEWLY DESCRIBED BIOMARKER ANALYSES IN SKIN &
SPINAL
FLUID INTO TRIAL TO ANALYZE RESPONSE TO TREATMENT FOR ENROLLED
PATIENTS
    * COMPLETED EVALUATION OF SAFETY AND STEADY-STATE
PHARMACOKINETICS
OF 200 MG DOSE OF IKT-148009 IN HEALTHY VOLUNTEERS
    * 11 SITES ARE ANTICIPATED TO BE SCREENING PATIENTS BY CLOSE
OF
APRIL, 2023 FOR '201' TRIAL
    * ANTICIPATED THAT 30 SITES WILL BE SCREENING PATIENTS BY
END OF
2Q23 FOR '201' TRIAL

Source text for Eikon:  ID:nPn7g5Z3Ha 
Further company coverage:  IKT.O 

 ((Reutersbriefs@thomsonreuters.com;))